Abstract Decades of basic and translational studies have identified the mechanisms by which pancreatic cancer cells use molecular pathways to hijack the normal homeostasis of the pancreas, promoting pancreatic cancer initiation, progression, and metastasis, as well as drug resistance. These molecular pathways were explored to develop targeted therapies to prevent or cure this fatal disease. Regrettably, the studies found that majority of the molecular events that dictate carcinogenic growth in the pancreas are non-actionable (potential non-responder groups of targeted therapy). In this review we discuss exciting discoveries on CCN-siblings that reveal how CCN-family members contribute to the different aspects of the development of pancreatic cancer with special emphasis on therapy.
Introduction
Human pancreatic ductal adenocarcinoma (PDAC) is a common form of human pancreatic cancer (PC) with a 5-year survival rate of less than 5 % after diagnosis and treatment, indicating the dire need for improved therapy (Grote and Logsdon 2007; Han and Von Hoff 2013; Hidalgo 2010) . PDAC develops through the accumulation of multiple genetic lesions, which lead to sequential, atypical, histological, preneoplastic changes, also known as pancreatic intraepithelial neoplasms (PanINs) and ultimately invasive/ metastatic PDAC (Abraham et al. 2003; Abramson et al. 2007; Aguirre et al. 2003; Aguirre et al. 2004; Banerjee et al. 2000; Caldas et al. 1994; Goggins 2005; Griffin et al. 1994; Keleg et al. 2003; Kern et al. 2002; Maitra et al. 2003; Maitra et al. 2002; Ottenhof et al. 2011; Reichert and Rustgi 2011; Stromnes and Greenberg 2016; Wilentz et al. 1998; Zhang et al. 1997) . The earliest detectable mutations identified in precursor lesions are activating mutations of K-Ras, which is detected in~95 % of PDACs (Banerjee et al. 2000; Eser et al. 2014; Huang et al. 2014; Kanda et al. 2012) . The genetically engineered mouse models (GEMMs) such as KC (LSLKras G12D /Pdx-1-Cre) indicates that activated K-Ras mutations are sufficient to induce acinar-to-ductal metaplasia (ADM) (Perera and Bardeesy 2012; Reichert and Rustgi 2011) followed by PanIN lesions, but these abnormalities rarely develop into invasive cancer (Abramson et al. 2007; Hingorani et al. 2005; Ying et al. 2012) . In contrast, KPC (LSL-Kras G12D / LSL-Trp53 R172H/+ /Pdx-1-Cre) GEMM harboring missense point mutations in p53 (Mutp53), along with K-Ras mutants, develop invasive and metastatic PDAC with drug resistance via gain-of-function activities compared to loss of heterozygosity or null mutations (Hanel et al. 2013; Lang et al. 2004; Olive et al. 2004; Weissmueller et al. 2014) . These findings recapitulate the cognate human condition (Kanda et al. 2013; Masciarelli et al. 2014; Olive and Tuveson 2006; Olivier et al. 2006 ) and thus, initially, Mutp53 was considered an attractive target to treat the PC progression and metastasis. However, efforts to target Mutp53 therapeutically have been challenging and have yet to make an impact on patient care (Lehmann and Pietenpol 2012; Levine and Oren 2009) . Therefore, efforts need to be focused on identifying the underlying novel mechanism(s) that suppress the downstream molecules of Mutp53 in PC cells or other pathways involved in the genesis of PDAC.
Despite multiple studies and clinical trials, the current therapeutic regimens for PDAC are (i) gemcitabine (Voutsadakis 2011) , (ii) combination therapy of nab-paclitaxel plus gemcitabine , (iii) Folfirinox (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil and leucovorin) (Conroy et al. 2011) and (iv) Onivyde (an irinotecan liposome injection) (WangGillam et al. 2016) . The median overall survival (OS) in these therapeutic groups remains modest, varying from 4 to 12 months with degradation of quality of life (Conroy et al. 2011; Mohammed et al. 2015; Von Hoff et al. 2013; WangGillam et al. 2016) . The limited efficacies of these drugs are due to the acquisition of chemo-resistant characteristics of PDAC. Multiple studies evaluating the mechanism of resistance to gemcitabine have been documented, and several genes' expressions and physiological changes (desmoplastic reaction) have been shown to correlate with the resistance mechanism (Blackstock et al. 2001; Damaraju et al. 2003; Duxbury et al. 2004; Galmarini et al. 2004; Merika et al. 2012; Nakahira et al. 2007 ). However, the modus operandi of drug resistance is still a mystery.
As the PDAC progresses from PanINs to invasive capacity, members of the CCN (Cyr61-CTGF-NOV) family of regulatory elements unveil malfunctions, thereby creating anomalous signaling circuitries that ultimately assist in promoting cancer initiation and progression, as well as drug resistance, culminating in a fatal disease. In this review, we propose to specifically address the role of CCN-family proteins in regulation of PDAC.
The molecular skeleton of the CCN family and their biological significance CCN is a small family of matricellular proteins with different homologs in different vertebrate species (Banerjee and Banerjee 2012; Brigstock 2003; Jun and Lau 2011; Lau 2016; Perbal 2001; Perbal 2004) . In human, these siblings are Cyr61/ CCN1 (Cysteine rich 61), CTGF/CCN2 (Connective tissue growth Factor), CCN3, WISP-1/CCN4 (WNT1 inducible signaling protein 1), WISP-2/CCN5 (WNT1 inducible signaling protein 2) and WISP-3/CCN6 (WNT1 inducible signaling protein 3) with various synonyms (Li et al. 2015) . The CCNsiblings share four conserved, multimodular domains in all except CCN5, in which the C-terminal Cysteine-knot (CT) domain is absent (Banerjee and Banerjee 2012) (Fig. 1) . Each module has unique functions in CCN proteins but their presence is not necessarily critical for their functions. For example, the absence of module 4 in CCN5 does not revoke its ability to perform adhesion function in osteoblasts (Ball et al. 2003; Perbal 2004; Takigawa 2003) . CCN proteins have multifunction potencies that can be mediated through the interaction of each module with various proteins in different cells and tissues (Perbal 2001; Perbal 2004) . Moreover, the CCN family of proteins has many transcription variants though their biological implication is still unknown (Perbal 2001; Perbal 2004) .
The biological significances of CCN-siblings are multifaceted and can be mediated through their cognate receptors integrins with various combinations (Banerjee and Banerjee 2012; Haque et al. 2012; Jun and Lau 2011; Lau 2012) . The CCN-siblings are either positive or negative regulators of various biological and pathobiological events, depending on the cellular context (Perbal 2001; Perbal 2004) . These contexts include cell proliferation, differentiation, migration, angiogenesis, wound-healing and cancers (Banerjee and Banerjee 2012; Brigstock 1999; Brigstock 2002; Brigstock 2003; Ji et al. 2014; Lake and Castellot 2003; Leask 2010; Lin et al. 2003; Perbal 2001; Perbal 2004) . The unique biology of CCN-siblings now places them in an area of great interest in understanding the mechanisms of disease-progression and aiding in the development of mechanism-driven biomarkers that may lead to the discovery of new drug designs.
Why CCN-siblings are targetable in pancreatic cancer?
Like other cancers, pancreatic cancer (PC) is a Bmixed-bag^of cells with heterogeneous behavior of cancer cells. Despite having disagreement about the role of cancer stem cells in tumorigenesis (Kong et al. 2009 ), studies from our laboratories and others strongly suggest a small subpopulation of malignant PC cells, usually termed BPC-initiating cells/stem cells (PICs),^have true tumorigenic potential in a xenograft model as compared to the counterpart (non-side population) or parental cells (Haque et al. 2011; Hermann et al. 2007; Ji et al. 2009; Lee et al. 2008a; Lee et al. 2008b; Mimeault and Batra 2014; Vaz et al. 2013) . Like other cancer stem cells, PICs can be identified and separated from rest of the cancer cells based on specific features and protein markers, such as self-renewal, differentiation, sphere (pancosphere) formation ability under non-adherent conditions, tumorigenic potency in a xenograft model, resistance to chemotherapies and expression of CD44, CD24, ESA, CD133 and CXCR4 (surface markers) depending on the functional skills of PICs. CD133 and CXCR4 positive PICs are not only highly tumorigenic but these cells are highly resistant to gemcitabine and have a predisposition to metastasize (Hermann et al. 2007; Li et al. 2007; Simeone 2008) . Moreover, multiple studies, have demonstrated that PICs display upregulation of certain genes needed to maintain self-renewal, epithelial-mesenchymal transition (EMT) and stemness. Sonic hedgehog (SHh) is one such gene (Berman et al. 2003; Haque et al. 2011; Lee et al. 2008a; Thayer et al. 2003) . Despite substantial studies of the vital roles of PICs in PDAC progression and drug resistance, driver genes or signaling molecules that regulate PICs survival and maintenance have not been fully defined and, thus, it is difficult to develop drug target(s) to prevent, delay or cure the disease.
The studies on the role of CCN-siblings in regulation of pancreatic cancer development, differentiation, progression and drug resistance open a new window of research for understanding the mechanism of pancreatic carcinogenesis and highlighting the fine balance between the activities of CCNsiblings (Dhar et al. 2007; Haque et al. 2012; Haque et al. 2011; Leask 2011; Leask 2013; Maity et al. 2014; Neesse et al. 2013 ).
CCN1 overexpression increases PDAC progression
In an orthotopic mouse model of pancreatic cancer, CCN1 showed increased expression in metastatic lesions. This study suggested that interaction between CCN1 and integrins (αvβ3) may promote formation of peritoneal metastases (Holloway et al. 2005 ); yet, its importance in PC was not clearly understood until we uncovered the precise role of CCN1 in PC development (Fig. 2 ). Our studies demonstrate that when overexpressed in PC and its precursor lesions, CCN1 promotes proliferation, epithelial to mesenchymal transition (EMT), stemness, migration and the growth of xenograft tumors of PC cells (Haque et al. 2011; Leask 2011) . PC cellsecreted CCN1 enhances abnormal neovascularization (tumor angiogenesis) under in vitro and in vivo conditions (Maity et al. 2014) . Moreover, we found that CCN1 is a potent regulator of SHh expression via the integrins/Notch-1-signaling pathway. CCN1 activity was mediated, at least in part, through altering proteasome activity (Haque et al. 2012 ) (Leask 2011) . Finally, we found that the sensitivity of GEMCITABINE was increased in CCN1 silenced pancreatic cancer cells through unknown mechanisms (Banerjee, Personal communication) . Despite having functional dichotomy of CCN1 in some cancers (Chen et al. 2016; Jun and Lau 2011) , targeting CCN1 could be an ideal approach for PDAC therapy.
CCN2 is an important factor that promotes drug resistance in PC Although the location of the pancreas is one of the vital impediments for treatment and leads to late diagnosis and unresectability (Han and Von Hoff 2013 ), a major contributor to poor clinical outcomes in PC is chemoresistance. Currently, there are a few FDA-approved efficacious therapies for chemo-resistant patients that help improve survival for 4-11 months compared to the old standard of care (gemcitabine therapy) (Conroy et al. 2011; Han and Von Hoff 2013; Von Hoff et al. 2013; Von Hoff et al. 2009; Wang-Gillam et al. 2016) . Thereby, chemoresistance is still a challenging task for PC therapy. In PC, the therapeutic obstacle is due to PICs because these cells are resistant to radiation and chemotherapy (Donnenberg et al. 2009; Zhou et al. 2009 ). In addition, desmoplastic reaction (DR)/desmoplasia, a dynamic process regulated by a cross-talk of tumor cells and/or PICs and surrounding stroma, plays a critical role in chemo-resistance in human PC (Han and Von Hoff 2013; Mahadevan and Von Hoff 2007; Merika et al. 2012; Whatcott et al. 2012) . Desmoplasia leads to a significant increase in the production of dense and fibrous connective tissues, extracellular matrix proteins and proliferation of myofibroblast cells/active stellates cells (PSCs) (Whatcott et al. 2012 ). This reaction contributes to enhancing the tumor fluid pressure and chemoresistance (Mahadevan and Von Hoff 2007; Olive et al. 2009 ). As with human samples, desmoplasia is an easily recognizable event in orthotopic samples or spontaneous cancer in mice models (Mazur and Siveke 2012) (Banerjee, Personal communication and see in Fig. 3A) . Therefore, several preclinical studies in animal models, as well as clinical trials, have been undertaken to develop a novel therapy against desmoplasia in an attempt to overcome the chemoresistance. Since SHh, a secreted ligand of the Patched1 receptor and activator of Gli-family of transcription factors (Marigo et al. 1996) , is known to be a prime regulator of desmoplasia in pancreatic cancer (Bailey et al. 2008; Spivak-Kroizman et al. 2013) , an inhibitor of SHh was evaluated in both animal models and clinical trials with huge expectations. Although there were promising outcomes in animal studies (Olive et al. 2009 ), the Phase II human trial was terminated due to the ineffectiveness of the drug (Merika et al. 2012) . A recent study found that SHh-deficiency in PC may reduce desmoplastic burden, but surprisingly, this deficiency caused aggressive tumor growth (Rhim et al. 2014) . Thus, the SHh-inhibitors are still being investigated as possible treatment options.
Several other small molecules and agents were also evaluated either alone or in different combinations for translational research and clinical trials. Thus far, these therapies either have shown significant toxicity or proven ineffective in abolishing desmoplasia. Thus, it's our opinion that new drug development approaches are necessary to target desmoplasia. Nevertheless, this cannot be done outright; several factors are accountable and thus cannot be ignored. These factors include, but are not limited to, mutant p53 and tumor initiating cells/cancer stem cells because they are responsible for disease progression and resistance to therapy (Bullock and Fersht 2001; Fiorini et al. 2015; Lane and Hupp 2003; Masciarelli et al. 2014; Merika et al. 2012 ). Targeting mutant p53 or cancer stem cells or both is a challenging task and not yet possible. These limitations emphasize the need to identify new targets that are common to all important factors.
CCN2/CTGF could be a novel target to destroy the desmoplastic reaction as CCN2 is a profibrotic secretory growth factor that plays a vital role in tumor-stromal interaction and desmoplasia in PC (Charrier and Brigstock 2013; Neesse et al. 2013 ) (Banerjee, unpublished data) (Fig. 3B) . Moreover, studies found that treatment with a monoclonal antibody against CCN2 enhances drug delivery in the KPC (Kras LSL-G12D/+ /p53 LSL-R172H /Pdx1-Cre) spontaneous pancreatic cancer mouse model (Hingorani et al. 2005) , indicating CCN2 plays vital role within the tumor microenvironment mediating gemcitabine resistance (Neesse et al. 2013 ) and thereby CCN2 can be considered as an important string of the desmoplastic bow.
CCN3 regulation of PDAC growth and progression CCN3 is one of the founding members of the CCN-family and plays vital roles in tumorigenesis (Li et al. 2015; Planque and Perbal 2003) . The function of CCN3 in carcinogenesis is different in the context of tissue types and organs. In Wilm's tumor, glioma, rhabdomyosarcoma, chondrosarcoma, breast and prostate cancers, CCN3 acts as a tumor suppressor gene (Dobson et al. 2014; Gupta et al. 2001; Montero et al. 2012; Wu et al. 2014; Yu et al. 2003) , while CCN3 promotes cancer cell proliferation and tumor progression in bladder cancer and pancreatic cancer (Chen et al. 2014; Cui et al. 2014 ) and correlates with poor overall survival of colon cancer (Ueda et al. 2015) . Although the mechanism of CCN3 action is unclear, recent studies found that CCN3 is a positive regulator of EMT in pancreatic cancer .
CCN4 expression correlates with PDAC progression CCN4 appears to be a factor stimulating aggressive behaviors of various cancers (Chen et al. 2007; Davies et al. 2010; Davies et al. 2007; Gurbuz and Chiquet-Ehrismann 2015; Tian et al. 2007; Wang et al. 2006 ) except in lung cancer and prostate cancer cells where CCN4 exhibits contrast behavior (Ono et al. 2013; Soon et al. 2003) . A univariate and multivariate correlative analysis demonstrates that CCN4 may serve as a potential biomarker for PDA progression (Yang et al. 2015) .
PDAC progression is accompanied by killing CCN5 CCN5, which is a~29-35 kDa protein, could be considered as tumor suppressor gene in PDAC (Fig. 4) . Like colon and breast cancers, the CCN5 protein is overexpressed in normal and preneoplastic cells, but is mostly undetected or minimally detected in various pancreatic cancer cell lines and tissue samples (Banerjee and Banerjee 2012; Dhar et al. 2007; Russo and Castellot 2010; Sabbah et al. 2011; Saxena et al. 2001 ). Functional studies demonstrate that the exposure of pancreatic cancer cells to CCN5 recombinant protein reverses the EMT process (Dhar et al. 2007) , thereby suggesting that CCN5 silencing may promote tumor progression and drug resistance in PDAC. However, our knowledge about the mechanism of suppression of CCN5 expression in pancreatic cancer cells is very limited. Previously, we established that CCN5 expression can be blocked at the transcription level by gain-of-function of mutant p53 in non-invasive breast cancer epithelial cells (Dhar et al. 2008) . In parallel, we also demonstrated that CCN5 expression is inversely correlated with the expression of mutant p53 in pancreatic cancer cells (Dhar et al. 2007 ), though no link was detected with the K-Ras mutations in pancreatic cancer cells (Banerjee, unpublished data) . Collectively, we anticipate that mutant p53-mediated suppression of CCN5 is required to promote invasion, metastasis and drug resistance. Further studies are urgently needed to establish the role of CCN5 in prevention of PDAC progression and drug resistance, which help in classifying CCN5 protein as an actionable element (Carr et al. 2016 ) with practical overtone for targeted therapy.
Conclusions and future perspectives
Pancreatic ductal adenocarcinoma is the most common malignant disease in the human pancreas and is a deadly disease Fig. 3 (A) Detection of desmoplasia in orthotopic human PC xenograft mouse model using an ultrasound (Vevo2100)-guided injection (USGI) non-invasive technique, without surgery: Panc-1 aggressive pancreatic cancer cells (1x10 6 ) were orthotopically implanted into the mouse pancreas using USGI technique (Huynh et al. 2011) . After 2.5 months, tumor growths in the pancreas were detected by ultrasound and then documented after sacrificing the animals. For the detection of DR in PC samples, tissues were fixed in formalin, and H&E staining was carried out in tissue sections. (B) Diagrammatic illustration of Autocrine-paracrine regulation of CCN2 during desmoplasia and chemoresistance Fig. 4 Diagrammatic representation of CCN5 regulation of invasive phenotypes of pancreatic cancer cells. CCN5 is overexpressed and functionally active in normal microenvironment of pancreatic epithelial cells and its expression could be suppressed in PC cells by mutant p53 gain-of-function. Therapeutic application of CCN5 or ectopic overexpression of CCN5 suppresses EMTosomes (regulators of EMT) activity resulted reverses invasive phenotypes of PC cells across all ethnic backgrounds. One of the main reasons it has such a poor prognosis is that it is almost always detected at an advanced stage in the majority of patients already have invasive phenotypes (i.e., multiple genomic aberrations, desmoplasia and metastatic growth in distant organs) at the time of diagnosis. These invasive phenotypes make pancreatic cancer cells insensitive to many chemotherapeutic drugs including gemcitabine, folfirinox and nab-paclitaxel. Thus, new ways to combat this disease are urgently needed.
Over a decade of studies indicates that the dysregulated expression of CCN-siblings (e.g. CCN1, CCN2, CCN3, CCN4 and CCN5) play key roles in pancreatic cancer progression and drug resistance (Dhar et al. 2007; Haque et al. 2012; Haque et al. 2011; Neesse et al. 2013 ). Thereby, anti-CCN strategies notably anti-CCN2 therapeutics should be considered as potentially viable strategies to block pancreatic cancer. However, a complete map and understanding of the regulatory landscape is lacking. In particular, a major gap exists in our understanding of how CCN-siblings regulate cancer cells and their microenvironments. Do they regulate and cross-talk to each other, resulting in cancer progression? If so then what oncogenic signaling is required for this anarchy? These findings, along with the existing body of work, will open new doors into our understanding of cancer etiology and future targeted therapy.
